Bariatric Surgery Significantly Outperforms Semaglutide and Tirzepatide for Long-Term Weight Loss
Background
The global epidemic of obesity and its comorbidities, such as Type 2 diabetes, necessitates highly effective and sustainable treatment strategies. While new anti-obesity medications (AOMs) like GLP-1 receptor agonists (GLP-1RAs) have shown remarkable efficacy, their real-world effectiveness relative to established bariatric surgical procedures, specifically sleeve gastrectomy and gastric bypass, remains a critical gap. Direct comparative data is essential for guiding clinical decisions and patient counseling in severe obesity management.
Study Design
This retrospective, real-world study analyzed data from 44,025 adults with BMI ≥35 across two urban health systems from 2018 to 2024. Patients received either injectable semaglutide or tirzepatide, or underwent sleeve gastrectomy or gastric bypass. Total weight loss (TWL) was compared up to 3 years post-treatment using inverse probability weighting and mixed linear models. Both intention-to-treat (any GLP-1RA use) and per-protocol (1 year of continuous GLP-1RA orders) analyses were conducted to assess the effectiveness of these interventions.
Results
Bariatric surgery consistently demonstrated greater total weight loss compared to GLP-1RAs across all measured time points. In the intention-to-treat analysis, semaglutide (n=25,804) resulted in TWL of 5.4% (95% CI: 5.3%-5.6%) at 1 year, 6.5% (6.4%-6.7%) at 2 years, and 7.4% (7.3%-7.6%) at 3 years. Tirzepatide (n=7308) achieved TWL of 9.1% (8.9%-9.4%) at 1 year and 10.8% (10.2%-11.3%) at 2 years. In contrast, sleeve gastrectomy (n=8728) led to TWL of 24.4% (24.3%-24.6%) at 1 year, 22.4% (22.3%-22.5%) at 2 years, and 22.0% (21.8%-22.1%) at 3 years. The most significant weight loss was observed with gastric bypass (n=2185), showing TWL of 29.8% (29.7%-29.9%) at 1 year, 28.1% (28.0%-28.2%) at 2 years, and 28.4% (28.3%-28.5%) at 3 years. When considering patients with 1 year of continuous GLP-1RA use (per-protocol), semaglutide TWL increased to 7.2% (7.0%-7.4%) at 1 year, 8.0% (7.8%-8.2%) at 2 years, and 8.8% (8.6%-9.0%) at 3 years, while tirzepatide TWL reached 11.7% (11.4%-11.9%) at 1 year and 11.9% (11.5%-12.3%) at 2 years.
Gastric bypass yielded the highest 1-year total weight loss at 29.8% (95% CI: 29.7%-29.9%), significantly surpassing semaglutide (5.4%) and tirzepatide (9.1%) in the intention-to-treat analysis.
Key Findings
- Gastric bypass achieved the highest 1-year total weight loss at 29.8% (95% CI: 29.7%-29.9%).
- Sleeve gastrectomy resulted in 24.4% (95% CI: 24.3%-24.6%) total weight loss at 1 year.
- Tirzepatide led to 9.1% (95% CI: 8.9%-9.4%) total weight loss at 1 year (intention-to-treat).
- Semaglutide achieved 5.4% (95% CI: 5.3%-5.6%) total weight loss at 1 year (intention-to-treat).
- Continuous GLP-1RA use improved outcomes, with tirzepatide reaching 11.9% TWL at 2 years.
Why It Matters
This real-world comparison provides crucial evidence for patients and clinicians navigating treatment options for severe obesity. Bariatric surgery remains the most effective intervention for achieving substantial and sustained total weight loss, particularly for individuals with BMI ≥35. While semaglutide and tirzepatide offer significant weight loss benefits, they do not match the magnitude of surgical outcomes. This data reinforces the role of surgery as a gold standard for maximal weight reduction, while also validating GLP-1RAs as powerful pharmacological tools. For peptide users and biohackers, this highlights that while these medications are potent, they operate on a different scale of efficacy compared to surgical anatomical changes. Future protocols might explore combination therapies or sequential approaches, but for now, the choice depends on desired outcome magnitude and individual risk tolerance.
semaglutide
tirzepatide
bariatric surgery
obesity
weight loss
real-world-evidence